Schedules of Controlled Substances: Placement of Tianeptine in Schedule I

Document 2026-13821 is a Proposed Rule published by the Department of Justice in the Federal Register on July 8, 2026. The Drug Enforcement Administration proposes placing the substance tianeptine (7-[(3-chloro-6,11-dihydro-6-methyl-5,5- dioxidodibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid), including its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers whenever the existence of such isomers, esters, ethers, salts, and salts of isomers, esters, and ethers is possible, in schedule I of the Controlled Substances Act. If finalized, this action would impose the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle tianeptine. View the original at https://www.federalregister.gov/documents/2026/07/08/2026-13821/schedules-of-controlled-substances-placement-of-tianeptine-in-schedule-i.

No. Document 2026-13821 is not classified as economically significant under Executive Order 12866. Economically significant rules require OIRA review and are estimated to have impacts of $100 million or more per year.